Menu
Search
|

Menu

Close
X

Cellectis SA CLLS.OQ (NASDAQ Stock Exchange Global Market)

17.13 USD
+0.29 (+1.72%)
As of Feb 22
chart
Previous Close 16.84
Open 17.01
Volume 48,472
3m Avg Volume 40,189
Today’s High 17.35
Today’s Low 16.83
52 Week High 38.85
52 Week Low 15.35
Shares Outstanding (mil) 35.42
Market Capitalization (mil) 1,013.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.89 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
27
FY17
42
FY16
69
EPS (USD)
FY18
-1.538
FY17
-3.654
FY16
-2.305
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
20.98
6.29
Price to Book (MRQ)
vs sector
3.73
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
0.02
16.12
LT Debt to Equity (MRQ)
vs sector
0.01
11.38
Return on Investment (TTM)
vs sector
-27.62
14.45
Return on Equity (TTM)
vs sector
-27.69
15.96

EXECUTIVE LEADERSHIP

Andre Choulika
Chairman of the Board, Chief Executive Officer, Member of the Executive Board, Since 2000
Salary: €508,226.00
Bonus: --
David Sourdive
Deputy Chief Executive Officer, Executive Vice President Technical Operations, Member of the Executive Committee, Director, Since 2016
Salary: €312,670.00
Bonus: --
Eric Dutang
Chief Financial Officer, Member of the Executive Committee, Since
Salary: --
Bonus: --
Elsy Boglioli
Chief Operating Officer, Executive Vice President - Strategy and Corporate Development, Member of the Executive Committee, Since 2018
Salary: --
Bonus: --
Stephane Depil
Senior Vice President - Research and Development and Chief Medical Officer , Member of the Executive Committee, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8 rue de la Croix-Jarry
PARIS     75013

Phone: +331.81691600

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

SPONSORED STORIES